RCT·critical care, nutrition, clinical nutrition, gastroenterology, immunology·PMC10880344
Safety, feasibility, and impact on the gut microbiome of kefir administration in critically ill adults
BMC Medicine · 16 authors, 12 centres
AI SUMMARY
FIDELITY 100%
POPULATION54 critically ill patients with an intact gastrointestinal tract in an ICU setting
INTERVENTIONKefir administered in escalating doses (60 mL, 120 mL, then 240 mL daily)
COMPARISON
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This open-label phase I study assessed the safety and feasibility of administering kefir to 54 critically ill ICU patients. The intervention was deemed safe with no bacteremia and highly feasible, with 91% of doses administered.
Full summary
780 CHARS
This open-label phase I study evaluated the safety and feasibility of kefir administration in 54 critically ill ICU patients with an intact gastrointestinal tract. Kefir was given in escalating doses (60 mL, 120 mL, then 240 mL daily). Safety was monitored for adverse events like bacteremia, bloating, and aspiration. Feasibility was defined as delivering more than 75% of prescribed doses. The study found kefir administration was safe, with no bacteremia and minimal side effects, and feasible, with 91% of 359 prescribed doses successfully administered. Microbiome analysis showed no increase in α-diversity but a significant improvement in the Gut Microbiome Wellness Index. The findings support the safety and feasibility of kefir in this setting and warrant larger studies.
PICO
PPOPULATION
54 critically ill patients with an intact gastrointestinal tract in an ICU setting
IINTERVENTION
Kefir administered in escalating doses (60 mL, 120 mL, then 240 mL daily)
OOUTCOME
Incidence of adverse events (safety) and percentage of prescribed doses delivered (feasibility)
